About AmbioPharm
AmbioPharm is a company based in North Augusta (United States) founded in 2006 was acquired by Corden Pharma in May 2026. AmbioPharm has raised $24 million across 2 funding rounds from investors including The Carlyle Group and Corden Pharma. AmbioPharm operates in a competitive market with competitors including Enzene Biosciences, Hybio Pharmaceutical, Ocelot Bio, PolyPeptide and Maruho, among others.
- Headquarter North Augusta, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$24 M (USD)
in 2 rounds
-
Latest Funding Round
Not available
-
Investors
The Carlyle Group
& 1 more
-
Employee Count
Not available
-
Acquired by
Corden Pharma
(May 27, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of AmbioPharm
Unlock access to complete
Funding Insights of AmbioPharm
AmbioPharm has successfully raised a total of $24M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in AmbioPharm
AmbioPharm has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include The Carlyle Group and Corden Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are directed toward multiple sectors.
|
Locked | Locked | Locked | |
|
CDMO offering its services for small molecules, peptides, lipids and carbohydrates
|
Locked | Locked | Locked |
Investor details for AmbioPharm
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by AmbioPharm
Investment portfolio details for AmbioPharm
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - AmbioPharm
Detailed financials for AmbioPharm
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ambiopharm Comparisons
Peer comparison for AmbioPharm
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of AmbioPharm
AmbioPharm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enzene Biosciences, Hybio Pharmaceutical, Ocelot Bio, PolyPeptide and Maruho, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Company specializing in development of Biosimilars
|
|
| Locked | Locked | Locked |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| Locked | Locked | Locked |
Ocelot Bio is a CDMO specializing in peptide manufacturing services.
|
|
| Locked | Locked | Locked |
Proprietary, GMP-grade, and non-GMP peptides are manufactured by PolyPeptide Labs.
|
|
| Locked | Locked | Locked |
Conducts R&D and manufactures ethical drugs for healthcare applications.
|
Detailed competitors of AmbioPharm
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ambiopharm
Complete news archive for AmbioPharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AmbioPharm
AmbioPharm was founded in 2006 and raised its 1st funding round 8 years after it was founded.
AmbioPharm is headquartered in North Augusta, United States. It is registered at North Augusta, South Carolina, United States.
AmbioPharm is a funded company, having raised a total of $24M across 2 funding rounds to date.
AmbioPharm is the contract manufacturer of peptides and biopharmaceuticals which also offers GMP services like Peptide API production and non-GMP process development services like GLP-grade peptide supply for pre-clinical applications, custom peptides and non-peptidic small molecules for pre-clinical in-vitro, medicinal, and toxicology programs. It also provides vaccine development services for developing antigenic sequences, single antigens, Multi-Antigenic-Peptides (MAPS), and multiple peptide vaccine cocktails. In parallel, it also provides analytical and process development tools that monitor the process for side reactions, purity checks, API control and process minimization. The company also offers services for organic conjugation to small molecules, proteins, toxoids, antifungals, KLH, and PEG. They claim to have expertise in a wide range of halogenated chemicals, with core competencies in fluorination of APIs and advanced intermediates.
AmbioPharm's top competitors include Enzene Biosciences, Hybio Pharmaceutical and PolyPeptide.
AmbioPharm has 2 investors. Key investors include The Carlyle Group, and Corden Pharma.